课题基金 / 基金详情

Research Training in Pediatric Oncology

Research Training in Pediatric Oncology
儿科肿瘤学研究培训
批准号:
10646386
负责人:
SCOTT A ARMSTRONG
金额:
$44.59万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
未结题
起止时间:
2009-07-13 至 2025-06-30

项目摘要

项目成果

SCOTT A ARMSTRONG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT This is a competitive renewal application for training grant support in pediatric oncology. The goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population. To accomplish this goal we have engaged a diverse and outstanding training faculty that embraces multiple areas of basic (“wet bench”), translational and clinical research. This experienced and highly accomplished group includes members of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Boston Children's Hospital (BCH), and additional components of the Harvard Medical School (HMS). Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The T32 program provides training in oncology research at the postdoctoral level for 8 trainees, selected from the combined DFCI-BCH pediatric hematology/oncology fellowship program, who are in their second, third and fourth years of training. These fellows spend on average five to six years in a protected training environment with limited clinical responsibilities, and the proposed T32 renewal would continue to support three years of that training. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 45 years the DFCI-BCH fellowship program has trained over 200 individuals, many of whom are leaders of academic pediatric hematology/oncology programs. Continued T32 support will ensure the training of investigational pediatric oncologists, whose research will contribute immeasurably to the understanding and management of childhood cancers.
期刊论文(52)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1073/pnas.2118697119
发表时间: 2022-06-07
期刊: Proceedings of the National Academy of Sciences of the United States of America
影响因子: 11.1
作者: []
通讯作者:
Trends in conditional survival and predictors of late death in neuroblastoma.
神经母细胞瘤条件生存的趋势和晚期死亡的预测因素。
DOI: 10.1002/pbc.28329
发表时间: 2020
期刊: Pediatric blood & cancer
影响因子: 3.2
作者: [Olsen,HannahE, Campbell,Kevin, Bagatell,Rochelle, DuBois,StevenG]
通讯作者: DuBois,StevenG
DOI: 10.1038/s41588-018-0191-z
发表时间: 2018-09
期刊: Nature genetics
影响因子: 30.8
作者: [Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, He S, Krill-Burger JM, Root DE, Vazquez F, Tsherniak A, Hahn WC, Golub TR, Young RA, Look AT, Stegmaier K]
通讯作者: Stegmaier K
DOI: 10.1002/pbc.28559
发表时间: 2020-10
期刊: Pediatric blood & cancer
影响因子: 3.2
作者: [Liu KX, Collins NB, Greenzang KA, Furutani E, Campbell K, Groves A, Mullen EA, Shusterman S, Spidle J, Marcus KJ, Weil BR, Weldon CB, Frazier AL, Janeway KA, O'Neill AF, Mack JW, DuBois SG, Shulman DS]
通讯作者: Shulman DS
31
    The Center for Therapeutic Targeting of EWS-oncoproteins
    • 批准号:
      10671815
    • 项目类别:
    • 资助金额:
      $50.54万
    • 财政年份:
      2022
    • 负责人:
      SCOTT A ARMSTRONG
    • 依托单位:
    The Center for Therapeutic Targeting of EWS-oncoproteins
    • 批准号:
      10382013
    • 项目类别:
    • 资助金额:
      $19.83万
    • 财政年份:
      2021
    • 负责人:
      SCOTT A ARMSTRONG
    • 依托单位:
    Defining epigenetic mechanisms in NPM1c mutant leukemia
    • 批准号:
      10184546
    • 项目类别:
    • 资助金额:
      $40.36万
    • 财政年份:
      2021
    • 负责人:
      SCOTT A ARMSTRONG
    • 依托单位:
    Defining epigenetic mechanisms in NPM1c mutant leukemia
    • 批准号:
      10640846
    • 项目类别:
    • 资助金额:
      $39.55万
    • 财政年份:
      2021
    • 负责人:
      SCOTT A ARMSTRONG
    • 依托单位:
    海外基金